Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory?
The effect on thyroid function of GH administration to 66 adult patients with severe GH deficiency was studied. Seventeen patients were euthyroid, and 49 had central hypothyroidism and were adequately treated with L-T(4). Forty patients were assigned to a low recombinant human GH (rhGH) regimen (3 microg/kg body wt.d for 3 months followed by 6 microg/kg body wt.d for another 3 months) and 26 to a higher one (6 microg/kg body wt.d for 3 months followed by 12 microg/kg body wt.d for another 3 months). Serum IGF-I, TSH, free T(4) (FT(4)), free T(3) (FT(3)), reverse T(3), T(4)-binding globulin, and antithyroid autoantibody (TgAb and TPOAb) were measured in basal condition and after 3 and 6 months of therapy. Normalization of IGF-I levels was obtained after 6-month rhGH treatment in 67% of patients, independently from the dose, whereas a significant reduction in FT(4) and reverse T(3) levels was recorded (P < 0.01), without variations in all the other parameters studied, including serum TSH, FT(3), and T(4)-binding globulin circulating levels. Antithyroid autoantibodies were detected in 11 of 66 patients (16.6%). Eight of 17 (47%) euthyroid subjects and 9 of 49 (18.3%) central hypothyroid patients, despite adequate substitution at baseline, showed FT(4) levels under the normal range at the end of the study. Altogether, 17 of 66 patients (25.7%) worsened their thyroid function. This study shows that GH deficiency masks in a consistent number of adult patients a state of central hypothyroidism. Therefore, during rhGH treatment, a careful monitoring of thyroid function is mandatory to start or adjust L-T(4) substitutive therapy.
Porretti
Silvia
S
Institute of Endocrine Sciences, Inc., University of Milan, Ospedale Maggiore IRCCS, 20122 Milan, Italy.
Giavoli
Claudia
C
Ronchi
Cristina
C
Lombardi
Gaetano
G
Zaccaria
Marco
M
Valle
Domenico
D
Arosio
Maura
M
Beck-Peccoz
Paolo
P
D000328:Adult; D000368:Aged; D005260:Female; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D007037:Hypothyroidism / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008659:Metabolic Diseases / Q000150:complications; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D013961:Thyroid Gland / Q000503:physiopathology*; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use; D013997:Time Factors
D011994:Recombinant Proteins; D019382:Human Growth Hormone; D013974:Thyroxine